Article Correctness Is Author's Responsibility: Asthma drug in clinical trial to treat severe COVID-19 patients

The article below may contain offensive and/or incorrect content.

This shows coronavirusA new clinical trial is underway to test ibudilast, an asthma drug approved in Japan, for the treatment of severe COVID-19. Ibudilast is a MIF inhibitor. MIF is a gene that regulates immune response and is a driver of inflammation which results in the cytokine storm associated with coronavirus.